IP Library Granted Patent US 10,195,220
Granted Patent B2
US 10,195,220 · App. 14/771,285 · Granted Feb 5, 2019

Hydrogen sulphide compounds

Inventors: Asif Ahmed (West Midlands, GB); Keqing Wang (West Midlands, GB)
Assignee: ASTON UNIVERSITY
A61K31/675A61K31/095
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,195,220
App. No.
14/771,285
Granted
Feb 5, 2019
Kind
B2
Abstract

The application describes Hydrogen Sulphide (H 2 S), or a (H 2 S) generating compound or compound capable of stimulating H 2 S production in a pregnant subject, for use in the treatment of pre-eclampsia (PE) or fetal growth restriction.

Claims (24)

1. A method for treating pre-eclampsia or fetal growth restriction in a host animal, the method comprising administering to the host animal an effective amount of one or more compounds selected from the group consisting of ACS 14, ACS 83, ACS 84, ACS 85, S-diclofenac, GYY4137, H 2 S-sildenafil, ADT-OH, H 2 S-Latanoprost, and H 2 S-Sartans, and salts thereof.

2. A method for monitoring treatment of pre-eclampsia or impaired fetal growth in a host animal, the method comprising measuring the amount of H 2 S in the blood, serum or plasma of the host animal prior to treatment and comparing it to the amount of H 2 S after treatment with one or more compounds selected from the group consisting of ACS 14, ACS 83, ACS 84, ACS 85, S-diclofenac, GYY4137, H 2 S-sildenafil, ADT-OH, H 2 S-Latanoprost, and H 2 S-Sartans, and salts thereof.

3. The method of claim 1 for treating pre-eclampsia.

4. The method of claim 3 wherein the compound is S-diclofenac, or a salt thereof.

5. The method of claim 3 wherein the compound is ACS 14.

6. The method of claim 3 wherein the compound is GYY4137.

7. The method of claim 1 for treating fetal growth restriction.

8. The method of claim 7 wherein the compound is S-diclofenac, or a salt thereof.

9. The method of claim 7 wherein the compound is ACS 14.

10. The method of claim 7 wherein the compound is GYY4137.

11. The method of claim 3 wherein the compound is H 2 S-sildenafil.

12. The method of claim 3 wherein the compound is ADT-OH.

13. The method of claim 3 wherein the compound is H 2 S-Latanoprost.

14. The method of claim 3 wherein the compound is H 2 S-Sartans.

15. The method of claim 3 wherein the compound is ACS 83.

16. The method of claim 3 wherein the compound is ACS 84.

17. The method of claim 3 wherein the compound is ACS 85.

18. The method of claim 7 wherein the compound is H 2 S-sildenafil.

19. The method of claim 7 wherein the compound is ADT-OH.

20. The method of claim 7 wherein the compound is H 2 S-Latanoprost.

21. The method of claim 7 wherein the compound is H 2 S-Sartans.

22. The method of claim 7 wherein the compound is ACS 83.

23. The method of claim 7 wherein the compound is ACS 84.

24. The method of claim 7 wherein the compound is ACS 85.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2022
From: ASTON UNIVERSITY
To: MIRZYME THERAPEUTICS LIMITED
Reel/Frame 058909/0989 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2017
From: AHMED, ASIF; WANG, KEQING
To: ASTON UNIVERSITY
Reel/Frame 044016/0414 →
Priority Claims (1)
GB 1303649.6 · Mar 1, 2013 · national
Continuity (1)
Related Publication 20160129022A1 · May 12, 2016